McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center — Reading, Pennsylvania

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center is a clinical research site located in Reading, Pennsylvania, United States 19612-6052.

Crixeo Health Trust Score: 83/100 (GOOD). This profile has not yet been claimed by the site owner.

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center has participated in 45 clinical trials with 2 currently active.

Therapeutic areas: Breast Cancer, Head and Neck Cancer, Lymphoma.

Sponsors: NSABP Foundation Inc, Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group.

Sponsor Feasibility Report

Trust Score: 83/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center?

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center has a Crixeo Trust Score of 83/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center conducted?

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center has 45 clinical trials on record, with 2 currently active. Their work covers Breast Cancer, Head and Neck Cancer, Lymphoma.

Is McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center accredited by Crixeo Health?

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.